PFE Latest Press Releases

-- October 27, 2026 --

Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma Business Wire 6:45 AM

-- October 26, 2026 --

Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting Business Wire 1:41 PM

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market Globe Newswire 9:00 AM

-- October 24, 2026 --

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 Business Wire 11:18 AM

-- October 22, 2026 --

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly's Next Growth Chapter Globe Newswire 2:27 PM

-- October 14, 2026 --

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 Business Wire 6:45 AM

-- October 7, 2026 --

Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer Business Wire 12:57 PM

-- October 6, 2026 --

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 PRNewswire 7:31 PM

Pfizer Declares Fourth-Quarter 2026 Dividend Business Wire 10:00 AM

-- October 2, 2026 --

Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo Business Wire 11:15 AM

-- October 1, 2026 --

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Business Wire 2:30 AM

-- September 28, 2026 --

Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO Business Wire 6:45 AM

-- September 22, 2026 --

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts Business Wire 10:00 AM

-- September 15, 2026 --

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat Globe Newswire 9:00 AM

-- September 8, 2026 --

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- August 27, 2026 --

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine Business Wire 4:30 PM

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine Globe Newswire 4:30 PM

-- August 14, 2026 --

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Globe Newswire 1:00 AM

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Business Wire 1:00 AM

-- August 4, 2026 --

NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off PRNewswire 8:55 AM

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance Business Wire 6:45 AM

-- July 30, 2026 --

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo Business Wire 6:45 AM

-- July 29, 2026 --

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Business Wire 4:30 PM

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Globe Newswire 4:30 PM

-- July 22, 2026 --

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer Business Wire 4:30 PM

-- July 15, 2026 --

AM Best Affirms Credit Ratings of Blue Whale Re Ltd. Business Wire 10:04 AM

-- July 10, 2026 --

U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Business Wire 11:23 AM

-- June 24, 2026 --

Pfizer Declares Third-Quarter 2026 Dividend Business Wire 3:52 PM

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance Business Wire 2:10 PM

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market Globe Newswire 8:30 AM

-- June 23, 2026 --

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts Business Wire 10:00 AM

-- June 22, 2026 --

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire 4:30 PM

-- June 18, 2026 --

Pfizer Announces Chief Financial Officer Transition Business Wire 6:45 AM

-- June 9, 2026 --

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates Globe Newswire 9:44 AM

-- June 8, 2026 --

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need Business Wire 6:45 AM

-- June 6, 2026 --

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide Business Wire 9:00 AM